Form 4: Amphastar CFO Peters Boosts Equity Holdings

Amphastar Pharmaceuticals' CFO, EVP & Treasurer, William J. Peters, reported the acquisition of restricted stock units and stock options, alongside a tax-related disposition of shares.

Summary

• William J. Peters, CFO, EVP & Treasurer, and a Director of Amphastar Pharmaceuticals, Inc. (AMPH), reported transactions in the company's securities.
• On March 9, 2026, Peters acquired 58,693 shares of Common Stock in the form of restricted stock units (RSUs) at a price of $0. These RSUs are scheduled to vest in four equal annual installments beginning on March 9, 2027.
• Also on March 9, 2026, Peters acquired 121,071 Employee Stock Options with an exercise price of $19.21. These options vest in four equal annual installments beginning on March 9, 2027, and have an expiration date of March 9, 2036.
• On March 10, 2026, Peters disposed of 3,297 shares of Common Stock at a price of $18.91. These shares were withheld to satisfy tax liabilities associated with the vesting of RSUs.
• Following these transactions, Peters directly beneficially owns 177,036 shares of Common Stock and 121,071 Employee Stock Options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development. The significant grants of RSUs and stock options to a key executive like the CFO indicate strong alignment of management incentives with shareholder value, despite the routine tax-related share disposition.

Positives

• The acquisition of 58,693 restricted stock units (RSUs) at a price of $0 demonstrates a grant of equity compensation, aligning management's interests with long-term shareholder value.
• The grant of 121,071 Employee Stock Options further incentivizes management performance and ties compensation to the company's stock price appreciation.

Negatives

• A disposition of 3,297 shares of Common Stock occurred to cover tax liabilities related to RSU vesting, which is a common practice but results in a reduction of direct share ownership.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on insider transactions.

Industry Context

StockSavvy.ai notes that insider purchases or grants of equity, such as restricted stock units and stock options, are generally viewed by the market as a positive signal, indicating management's confidence in the company's future prospects and aligning their financial interests with those of shareholders. This activity by a key executive like the CFO is often interpreted as a sign of commitment to long-term value creation.

Stakeholder Impact

• Shareholders: The equity grants to the CFO align management's financial interests with shareholder value creation, potentially fostering greater confidence in the company's long-term performance.
• Employees: The compensation structure for a key executive may serve as a benchmark or signal for broader employee incentive programs.

Next Steps

• The restricted stock units and employee stock options will vest in four equal annual installments beginning on March 9, 2027.

Key Dates

Recommendation

A seasoned investor would likely maintain a 'hold' recommendation based on this Form 4 filing. While the significant grants of restricted stock units and stock options to the CFO are a positive signal, indicating management's confidence and alignment with shareholder interests, a Form 4 primarily reports transactional activity and does not provide sufficient fundamental or operational data to warrant a 'buy' or 'sell' recommendation on its own. It reinforces a positive sentiment but requires broader financial analysis for a definitive investment decision.

Keywords

Amphastar Pharmaceuticals, AMPH, Insider Transaction, Form 4, Restricted Stock Units, Stock Options, Executive Compensation, Equity Grant